Purpose of review
The purpose of this review is to provide an update concerning recent advances in the evidence- based study of serious infections
in patients with rheumatoid arthritis (RA) treated with biological drugs or conventional disease-modifying antirheumatic drugs (DMARDs), concentrating on studies published in the last 18 months.
New studies have further strengthened existing evidence relating the use of biological drugs to serious infections
. The risk does not seem to be any different with short-term or long-term use. There is still a lack of conclusive studies identifying biomarkers, but it is plausible that the drugs have direct effects on cytokines and cell activity and then serious infections
The frequent infections
of patients with RA may be due to the disease itself (altered immunological function, disability, immobility, joint surgery), extra-articular manifestations or DMARDs, immunosuppressants and steroids. The use of biological drugs lead to the development of serious infections
including tuberculosis. Patients should be informed of their increased risk, and physicians need to be aware of these complications and how to treat them.